Asceneuron is the second spin-off company from the EPP fund. The company is focused on the discovery and development of effective small molecule therapeutics for Alzheimer’s disease and related neurodegenerative diseases such as tauopathies. Asceneuron is based in Geneva, Switzerland

Team Member
more about
Hakan Goker
Latest News Entry
Asceneuron appoints J. Michael Ryan, M.D. as Chief Medical Officer

Lausanne, Switzerland, December 6, 2016 - Asceneuron SA, an emerging leader in the development of innovative small molecules for neurodegenerative diseases, today announced the appointment of J. Michael Ryan, M.D. as Chief Medical Officer. With over 15 years of Central Nervous System (CNS) clinical research experience, Michael brings extensive drug development expertise to Asceneuron. He will be responsible for advancing Asceneuron’s pipeline of innovative small molecules and progressing tau modifiers through the clinic.

all portfolio news